Psychedelic Medicine

Association

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Excerpts from the publication

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient’s readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient’s readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

Read more

Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

Drug–drug interactions involving classic psychedelics: A systematic review

Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review